Vitreoretinal Lymphoma: Optimizing Diagnostic Yield and Accuracy
- PMID: 34626574
- DOI: 10.1016/j.ajo.2021.09.032
Vitreoretinal Lymphoma: Optimizing Diagnostic Yield and Accuracy
Abstract
Purpose: To determine whether the addition of adjunctive tests, including immunohistochemistry (IHC), cytokine analysis, flow cytometry, and IgH gene rearrangement testing, achieves improved diagnostic parameters compared with cytologic smears alone in the detection of vitreoretinal lymphoma (VRL). To determine which of these tests or combination of tests provide the greatest diagnostic utility.
Design: Retrospective review to assess diagnostic value.
Methods: This single university-affiliated tertiary care center study included data from 237 vitreous biopsies performed between 1999 and 2017 in patients with suspected VRL. From 1999 to 2008-2009, cytologic smears were the sole test performed (84 cases). The protocol initiated in 2008-2009 added the 4 additional diagnostic tests (153 cases). The sensitivity, specificity, positive predictive value, negative predictive value, diagnostic accuracy, and diagnostic yield were calculated. Parameters were calculated for tests individually, for all 5 combined, and all possible 2-, 3-, and 4-test combinations. For cytologic smears, diagnostic parameters were calculated both before and after the addition of adjunctive tests to our protocol and for the entire cohort.
Results: Of the 237 vitreous biopsies, 50 samples (21%) were from patients with confirmed central nervous system lymphoma and/or actively treated central nervous system, systemic, or intraocular lymphoma. Diagnostic yields (95% CI) were 90% (85%-93%) for smears, 82% (72%-89%) for IHC, 91% (85%-96%) for cytokine analysis, 76% (67%-84%) for IgH gene rearrangement, and 50% (40%-60%) for flow cytometry. For smears, the sensitivity pre-protocol was 73% (39%-94%), compared with 87% (69%-96%) post-protocol. IgH gene rearrangement was the only test exhibiting low sensitivity (40%). The combination of smears, IHC, and cytokine analysis exhibited the highest diagnostic parameters, with sensitivity 92%, specificity 98%, and diagnostic yield 100%.
Conclusions: The combination of cytologic smears, IHC, and cytokine analysis seems to be a reasonable and sufficient protocol for the diagnosis of suspected VRL. IgH gene rearrangement and flow cytometry may be the most expendable tests from our protocol.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.JAMA Ophthalmol. 2018 Oct 1;136(10):1098-1104. doi: 10.1001/jamaophthalmol.2018.2887. JAMA Ophthalmol. 2018. PMID: 30027272 Free PMC article.
-
PreservCyt Is an Optimal Fixative that Permits Cytologic and Molecular Analyses of Vitreoretinal Lymphoma Biopsies.Ocul Immunol Inflamm. 2021 Apr 3;29(3):430-439. doi: 10.1080/09273948.2019.1636093. Epub 2019 Aug 16. Ocul Immunol Inflamm. 2021. PMID: 31418635
-
Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008. Oncotarget. 2017. PMID: 28002793 Free PMC article.
-
Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.Jpn J Ophthalmol. 2023 Jul;67(4):363-381. doi: 10.1007/s10384-023-00997-6. Epub 2023 May 20. Jpn J Ophthalmol. 2023. PMID: 37209195 Review.
-
Primary vitreoretinal lymphoma: empowering our clinical suspicion.Curr Opin Ophthalmol. 2019 Nov;30(6):491-499. doi: 10.1097/ICU.0000000000000620. Curr Opin Ophthalmol. 2019. PMID: 31589186 Review.
Cited by
-
Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).Eye Vis (Lond). 2025 May 26;12(1):20. doi: 10.1186/s40662-025-00434-4. Eye Vis (Lond). 2025. PMID: 40414948 Free PMC article. Review.
-
Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.Blood Sci. 2025 May 1;7(2):e00233. doi: 10.1097/BS9.0000000000000233. eCollection 2025 Jun. Blood Sci. 2025. PMID: 40322320 Free PMC article. Review.
-
Molecular diagnosis of vitreoretinal lymphoma.Taiwan J Ophthalmol. 2024 Dec 24;15(2):236-244. doi: 10.4103/tjo.TJO-D-24-00052. eCollection 2025 Apr-Jun. Taiwan J Ophthalmol. 2024. PMID: 40584202 Free PMC article. Review.
-
Update in Molecular Testing for Intraocular Lymphoma.Cancers (Basel). 2022 Sep 20;14(19):4546. doi: 10.3390/cancers14194546. Cancers (Basel). 2022. PMID: 36230469 Free PMC article. Review.
-
Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: a single tertiary center experience.Sci Rep. 2023 Mar 18;13(1):4478. doi: 10.1038/s41598-023-31414-0. Sci Rep. 2023. PMID: 36934118 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical